Remove 2025 Remove Eating disorders Remove Sleep and mental health
article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

MindMed initiated a phase 3 study of MM120 for major depressive disorder, with results expected in the second half of 2026. The second quarter of 2025 saw some huge successes and fails in the psychiatric treatment pipeline. What percentage of 2025 Q2 psychiatric pipeline news was positive vs negative?

article thumbnail

Introducing the Borderline Personality Disorder Inventory

Psychiatric Times

Developed with input from international mental health professionals, the BPD-I™ is freely available for clinical use, education, and research. SHOW MORE Discover the innovative Borderline Personality Disorder Inventory (BPD-I™), a psychodynamically-informed tool for assessing BPD symptoms effectively.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What Is a Sleep Disorder? A Harmful Dysfunction Analysis

Psychiatric Times

A Harmful Dysfunction Analysis Author(s): Jean-Arthur Micoulaud-Franchi, MD, PhD , Christophe Gauld, MD, PhD +2 More Key Takeaways Sleep medicine lacks a structured definition for disorders, complicating diagnosis and classification compared to psychiatry's DSM framework. SHOW MORE What is a sleep disorder?

article thumbnail

The 2025 Summer Heatwave: Implications for Patients With Psychiatric Disorders

Psychiatric Times

Ms Barbee has a passion to reduce the stigma around mental health and promoting increased access to mental health care and education of both clinicians and the general public. Related Videos Related Content Advertisement June 13th 2025 Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score John J.

article thumbnail

Brief Book Reviews: July 2025

Psychiatric Times

Higgins, MD These 2 compelling memoirs delve into the complexities of schizophrenia, showcasing resilience, friendship, and the impact of mental health. While this is an extraordinary accomplishment for someone with a serious mental illness, reading between the lines, it seems that Laudor lost some cognitive skills due to the illness.

article thumbnail

COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

Psychiatric Times

The COMP005 trial is the first phase 3 study of synthetic psilocybin, marking a milestone in psychedelic research for mental health. No unexpected safety issues or imbalance in suicidal ideation were observed between treatment and placebo groups. points (95% CI [-5.7, -1.5]) in change at the primary endpoint.

article thumbnail

Exploring NMDA Antagonists for MDD

Psychiatric Times

Presented at: Southern California Psychiatry Conference; July 11-12, 2025; Huntington Beach, CA. Accessed July 11, 2025. January 21, 2025. Related Videos Related Content Advertisement July 11th 2025 Are You Ready for the Southern California Psychiatry Conference? Psychiatric Times. May 19, 2022. Psychiatric Times.